Biofortuna to Use TriLink dNTPs in Diagnostic PCR Kits

Biofortuna will use the dNTPs for a line of human leukocyte antigen diagnostic kits it is developing for the transplantation, blood grouping, disease identification, and pharmacogenetic markets.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.